The American pharmaceutical giant Merck & CO recently announced that they have reached a clinical cooperation with Immune Design. They will use G100 and LV305 immunotherapies developed by Immune Designthey and Merck’s PD-1 immunotherapy Keytruda to make a kind of therapeutic cocktail. Now in step-I clinical study they are evaluating the therapeutic cocktail’s potential to cure NHL and melanoma.

The step-I clinical study will be carried out in patients with local radiation therapy of follicular NHL and will evaluate the efficacy and safety of G100 combined with intravenous injection of Keytruda. The second step-I clinical trial will be conducted in patients with melanoma who have not yet achieved remission for 3 months and will evaluate the safety and therapeutic response of LV305 and Keytruda combination therapy.

G100 and LV305 are two immunotherapies developed by Design Immune based on their GLAAS and ZVex platforms. Through the induction and proliferation of anti-tumor CD8+T cells, anti-tumor activity of the immune system will be activated. Different from other T cell therapies that require the manipulation of individual in vitro, the 2 medicines are designed to develop the "off-the-shelf" immune therapy.